Bundling Among Rivals: A Case of Pharmaceutical Cocktails
44 Pages Posted: 30 Aug 2010 Last revised: 5 Feb 2021
Date Written: August 2010
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the bundle in her office from the component drugs. We show that a less competitive equilibrium arises with cocktail products because firms can internalize partially the externality their pricing decisions impose on competitors. The incremental profits from creating a bundle are sometimes as large as the incremental profits from a merger of the same two firms.
Suggested Citation: Suggested Citation